Antivert

Pellagra, Hardening of the Arteries, dietary supplementation + 14 more
Treatment
8 FDA approvals
20 Active Studies for Antivert

What is Antivert

NiacinThe Generic name of this drug
Treatment SummaryMeclizine is a medication that helps to reduce the symptoms of motion sickness and vertigo. It works by blocking histamine in the brain, and can also have calming effects on the central nervous system. Meclizine is generally prescribed to be taken orally as tablets, and is available under the brand name Antivert in the U.S.
O-Cal FA multivitaminis the brand name
image of different drug pills on a surface
Antivert Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
O-Cal FA multivitamin
Niacin
1970
106

Approved as Treatment by the FDA

Niacin, also known as O-Cal FA multivitamin, is approved by the FDA for 8 uses which include High Cardiovascular Risk and Hyperlipidemia .
High Cardiovascular Risk
Used in combination with other therapies
Hyperlipidemia
Used in combination with Sevelamer to help manage Hyperlipidemias
Hardening of the Arteries
Used in combination with Sevelamer to help manage Atherosclerosis
High Cholesterol
Used in combination with Sevelamer to help manage Hyperlipidemias
Coronary Artery Disease
Used in combination with Sevelamer to help manage history of coronary artery disease
dietary supplementation
Used in combination with Niacin for dietary supplementation
Primary Hypercholesterolemia
Used in combination with other therapies
Dietary Modifications
Used in combination with other therapies

Effectiveness

How Antivert Affects PatientsMeclizine is used to reduce nausea, vomiting, or dizziness, particularly caused by motion sickness or problems with the vestibular system. It usually starts working within an hour and can last up to 24 hours. Meclizine can cause drowsiness due to its effects on the brain.
How Antivert works in the bodyVomiting is a reflex that is regulated by an area in the brain called the CTZ. This area sends signals to another area called the vomiting center. Different receptors, such as histamine, serotonin, and dopamine, are found in the brainstem and can trigger a vomiting response. Meclizine works by blocking the histamine receptors in the vestibular nuclei and the nucleus of the solitary tract, thus preventing signals from reaching the vomiting center. Meclizine may also reduce stimulation of the area that controls balance and coordination.

When to interrupt dosage

The advised dose of Antivert is contingent upon the determined affliction, such as Disease, Vertigo and Airsickness. The amount of dosage is dependent on the method of delivery outlined in the table below.
Condition
Dosage
Administration
Combined Modality Therapy
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, Delayed Release, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Kit
Dietary Modifications
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, Delayed Release, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Kit
Coronary Artery Disease
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, Delayed Release, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Kit
Risk of pancreatitis
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, Delayed Release, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Kit
inadequate response to diet
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, Delayed Release, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Kit
Hypertriglyceridemia
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, Delayed Release, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Kit
High Cholesterol
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, Delayed Release, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Kit
Hardening of the Arteries
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, Delayed Release, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Kit
dietary supplementation
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, Delayed Release, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Kit
Primary Hypercholesterolemia
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, Delayed Release, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Kit
cholesterol
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, Delayed Release, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Kit
Myocardial Infarction
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, Delayed Release, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Kit
Hyperlipidemias
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, Delayed Release, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Kit
Triglycerides
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, Delayed Release, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Kit
Dyslipidemias
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, Delayed Release, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Kit
Pellagra
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, Delayed Release, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Kit
High Cardiovascular Risk
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Lozenge, Liquid - Oral, Solution, Liquid, Capsule, extended release, Capsule, extended release - Oral, Powder, Powder - Oral, Lozenge - Oral, Tablet, extended release; Tablet, multilayer, extended release - Oral, Tablet, extended release; Tablet, multilayer, extended release, Solution / drops, Tablet, chewable - Oral, Tablet, chewable, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Solution / drops - Oral, Tablet, Delayed Release, Kit - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Kit

Warnings

Antivert Contraindications
Condition
Risk Level
Notes
Hypervitaminosis
Do Not Combine
Liver Dysfunction
Do Not Combine
Transaminases
Do Not Combine
Hemorrhage
Do Not Combine
Liver Diseases
Do Not Combine
Peptic Ulcer
Do Not Combine
Transaminases
Do Not Combine
There are 20 known major drug interactions with Antivert.
Common Antivert Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Niacin.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Niacin.
Acenocoumarol
Major
The metabolism of Acenocoumarol can be decreased when combined with Niacin.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Niacin.
Alpelisib
Major
The metabolism of Alpelisib can be decreased when combined with Niacin.
Antivert Toxicity & Overdose RiskThe lowest toxic dose of meclizine in mice has been found to be 1600mg/kg when administered orally and 625mg/kg when administered intraperitoneally. In rats, the lowest toxic dose is 800mg/kg when administered orally. Symptoms of overdose may include extreme drowsiness, coma, seizures, and low blood pressure (especially in the elderly). In children, overdose may produce anticholinergic effects and hallucinations. Treatment for meclizine overdose includes supportive care and, if taken recently, inducing vomiting or using a gastric lavage to limit further absorption. Physostigmine may be used to counteract
image of a doctor in a lab doing drug, clinical research

Antivert Novel Uses: Which Conditions Have a Clinical Trial Featuring Antivert?

10 active trials are presently investigating the potential of Antivert to mitigate Disease, Airsickness and Vertigo symptoms.
Condition
Clinical Trials
Trial Phases
Coronary Artery Disease
0 Actively Recruiting
dietary supplementation
0 Actively Recruiting
High Cholesterol
17 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Early Phase 1
Dyslipidemias
1 Actively Recruiting
Phase 2
Pellagra
0 Actively Recruiting
cholesterol
4 Actively Recruiting
Phase 3, Not Applicable
Hyperlipidemias
0 Actively Recruiting
Risk of pancreatitis
0 Actively Recruiting
Hardening of the Arteries
18 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Phase 3
Primary Hypercholesterolemia
8 Actively Recruiting
Phase 3, Phase 2, Not Applicable
Combined Modality Therapy
0 Actively Recruiting
High Cardiovascular Risk
2 Actively Recruiting
Phase 2, Phase 3
Dietary Modifications
3 Actively Recruiting
Early Phase 1, Not Applicable, Phase 2
Triglycerides
0 Actively Recruiting
Hypertriglyceridemia
6 Actively Recruiting
Phase 3, Phase 2
Myocardial Infarction
0 Actively Recruiting
inadequate response to diet
0 Actively Recruiting

Antivert Reviews: What are patients saying about Antivert?

5Patient Review
10/26/2013
Antivert for Sensation of Spinning or Whirling
I unfortunately did not experience any relief from my vertigo after using this medication.
5Patient Review
2/3/2012
Antivert for Sensation of Spinning or Whirling
4.7Patient Review
3/3/2012
Antivert for Sensation of Spinning or Whirling
4.7Patient Review
4/26/2012
Antivert for Sensation of Spinning or Whirling
4.3Patient Review
2/3/2016
Antivert for Sensation of Spinning or Whirling
This medication always makes me sleepy, but it's really effective when I'm in a lot of pain and can't walk because of dizziness. I've been using it for 15 years, only as needed.
4.3Patient Review
4/30/2016
Antivert for Sensation of Spinning or Whirling
I've had vertigo three times now and this medication always seems to help. However, I do get very drowsy after taking it.
4Patient Review
3/31/2013
Antivert for Sensation of Spinning or Whirling
I have vertigo that comes and goes, and I'm not sure if this drug helps with that or not. However, I do know that it makes me feel incredibly sleepy to the point where I can't function.
4Patient Review
3/29/2013
Antivert for Sensation of Spinning or Whirling
I have had this problem for 40 years and, unfortunately, this treatment did not help.
3Patient Review
1/25/2016
Antivert for Sensation of Spinning or Whirling
These pills work well to keep spinning-induced nausea at bay, but they make me very drowsy.
2.3Patient Review
12/13/2011
Antivert for Sensation of Spinning or Whirling
2.3Patient Review
7/26/2012
Antivert for Sensation of Spinning or Whirling
This treatment helps me when I'm feeling vertigo, though it's not a perfect solution.
2Patient Review
11/30/2011
Antivert for Sensation of Spinning or Whirling
1.7Patient Review
11/27/2015
Antivert for Sensation of Spinning or Whirling
Though it does help with vertigo, this medication unfortunately also very significantly impairs my energy levels and motivation.
1Patient Review
10/28/2014
Antivert for Sensation of Spinning or Whirling
Meclizine did nothing to help with my dizzy spells. If anything, they got worse when I was taking the medication. I only found relief after quitting the meds and flushing them out of my system.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about antivert

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Antivert sold over the counter?

"Antivert and Bonine are both available to purchase, however Antivert is only obtainable through a prescription whereas Bonine can be bought over-the-counter. They have similar side effects such as blurred vision, dry mouth and drowsiness, however Antivert also has constipation, dizziness, headache, vomiting and tiredness as additional side effects."

Answered by AI

How long does it take for Antivert to work for vertigo?

"The bottom line is that meclizine can be used to treat vertigo or nausea and vomiting caused by motion sickness. However, it takes about an hour to start working and may cause drowsiness, although it is less likely to cause drowsiness than some other antihistamines."

Answered by AI

What does Antivert do for vertigo?

"Antivert is a medication used to prevent or treat nausea, vomiting, and dizziness caused by motion sickness. It may also be used to reduce lightheadedness, dizziness, and loss of balance (vertigo) caused by diseases that affect the inner ear."

Answered by AI

What is the medication Antivert used for?

"Meclizine is an antihistamine that is used to prevent and treat nausea, vomiting, and dizziness caused by motion sickness. It may also be used to reduce dizziness and loss of balance (vertigo) caused by inner ear problems."

Answered by AI

Clinical Trials for Antivert

Image of The Worship Center Cristian Church in Birmingham, United States.

Black Impact for Heart Health

18+
Male
Birmingham, AL
The goal of this clinical trial is to evaluate the implementation and effectiveness of the Black Impact program-a church-based cardiovascular health (CVH) intervention-in Black men aged 35-70 who are at risk for heart disease, diabetes, obesity, and related conditions. The main questions this study aims to answer are: * Does participation in the Black Impact program improve cardiovascular health metrics (e.g., blood pressure, cholesterol, blood sugar) and health behaviors among Black men at The Worship Center Christian Church (TWC)? * What factors influence the adoption, delivery, and sustainability of the Black Impact program in a faith-based setting? Researchers will compare an immediate-start intervention group and a delayed-start (waitlist control) group to assess both short-term health outcomes and program implementation factors. Participants will: * Attend a 90-minute weekly session for 24 weeks, including 45 minutes of physical activity led by a certified trainer and 45 minutes of health education delivered by trained coaches. * Receive one-on-one support from a community health worker to reduce barriers to care and engage with primary care. * Complete biometric health screenings and surveys at baseline, 12 weeks, and 24 weeks to assess clinical and behavioral outcomes. * Use a smartwatch, blood pressure cuff, and other tools to track progress in real time. * Participate in exit focus groups or interviews to share feedback about the intervention. * A subset of TWC leaders and interventionists (N=15) will also be interviewed to assess implementation, resource needs, and sustainability. This study uses the RE-AIM framework to assess Reach, Effectiveness, Adoption, Implementation, and Maintenance, and aims to inform scalable strategies for improving CVH among Black men in trusted community settings.
Waitlist Available
Has No Placebo
The Worship Center Cristian Church
Have you considered Antivert clinical trials? We made a collection of clinical trials featuring Antivert, we think they might fit your search criteria.Go to Trials
Image of Lipid Clinic at Brown University Health in Providence, United States.

2-HOBA Supplementation for High Cholesterol

18 - 69
All Sexes
Providence, RI
The goal of this clinical trial is to learn if a natural supplement called 2-hydroxybenzylamine (2-HOBA) can reduce harmful oxidized lipids and improve the function of lipoprotein(a) in adults with high lipoprotein(a) levels. The main questions it aims to answer are: Does 2-HOBA lower oxidized phospholipids on lipoprotein(a)? Does 2-HOBA reduce markers of inflammation and blood clotting in the blood? Participants will: Take 2-HOBA capsules (400 mg, three times daily with meals) for 6 weeks Provide blood and urine samples at the beginning, middle, and end of the study Have lab tests to measure changes in lipids, inflammation, and clotting markers
Waitlist Available
Has No Placebo
Lipid Clinic at Brown University HealthWenliang Song, MD
Image of Sidney & Lois Eskenazi Hospital in Indianapolis, United States.

Composite Intervention for Metabolic Syndrome

18+
All Sexes
Indianapolis, IN
The objective of this study is to pilot a multifaceted, optimized intervention for metabolic syndrome (MetS) in emergency department patients to establish feasibility. Participants (n=20) will be randomized to intervention or control (usual care). The composite intervention will include an educational video outlining the adverse effects of MetS and the benefit of walking, a written exercise prescription with a defined goal of walking 150 minutes per week, a Fitbit accelerometer device, resources for healthy eating practices, periodic text message reminders, and an urgent referral to primary care and our health system's Healthy Me clinic for follow-up visit. Investigators hypothesize that this approach will change patient understanding and motivation to increase physical activity and healthy eating habits.
Recruiting
Has No Placebo
Sidney & Lois Eskenazi Hospital
Have you considered Antivert clinical trials? We made a collection of clinical trials featuring Antivert, we think they might fit your search criteria.Go to Trials
Image of University of Alabama at Birmingham in Birmingham, United States.

Inspire HER for Cardiovascular Disease

30 - 79
Female
Birmingham, AL
Poor heart health puts Black women at risk for a shorter life with more illness than people of any other non-indigenous racial group. We will refine and conduct a randomized, wait-list controlled trial of Inspire HER (a heart health lifestyle intervention for Black women that provides health education, physical activity, and social resources). We will also compare Inspire HER and Black Impact (a heart health intervention for Black men) data to study how women and men respond differently to stress. This trial aligns with American Heart Association's pledge to address heart health equity through new interventions that consider the person and the circumstances with which they live.
Waitlist Available
Has No Placebo
University of Alabama at BirminghamTimiya S Nolan, PhD
Image of Rush University Medical Center in Chicago, United States.

Health Coaching for Heart Disease

40 - 75
All Sexes
Chicago, IL
The goal of this longitudinal study is to investigate the role of virtual health coaching on mitigation of cardiometabolic disease risk in an underserved, food insecure population. The main questions it aims to answer are: * Does longitudinal, individualized health coaching directed at lifestyle modification reduce patient 10-year risk of heart attack or stroke? * Does longitudinal, individualized health coaching directed at lifestyle modification reduce rates of hypertension, hyperlipidemia, and diabetes? * Does longitudinal, individualized health coaching directed at lifestyle modification improve accessibility to healthcare? Researchers will investigate the effects of regularly scheduled health coaching sessions on composite cardiometabolic risk profile as well as individual modifiable cardiovascular risk factors. Participants will: * Participate in in-person cardiovascular screening, occuring at the time of enrollment, months 3 and 6. * Engage in virtual health coaching sessions to talk about diet, exercise, weight loss, blood pressure and diabetes control, and accessibility to healthcare * Keep a log of their blood pressure
Waitlist Available
Has No Placebo
Rush University Medical CenterDaniel Luger, MD
Image of (Benedict) UMass Memorial Medical Center - Adult Primary Care in Worcester, United States.

WE CARE SDOH System for Chronic Disease

Any Age
All Sexes
Worcester, MA
The goal of this clinical trial is to learn if the implementation of the WE CARE social determinants of health (SDOH) screening and referral intervention with an antiracist lens in primary care settings can lead to a meaningful decrease in chronic disease by monitoring conditions such as hypertension, diabetes, depression, hyperlipidemia, and asthma through clinical measures. The main question it aims to answer is: Does the WE CARE SDOH screening and referral intervention applying an antiracism lens informed implementation strategies have the potential to reduce racial/ethnic health inequities in chronic diseases for minoritized patients?
Recruiting
Has No Placebo
(Benedict) UMass Memorial Medical Center - Adult Primary Care (+2 Sites)
Image of Clinical Research Site 4 in Santa Clarita, United States.

Plozasiran for Hypertriglyceridemia

18+
All Sexes
Santa Clarita, CA
This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to other etiologies, with at least one occurring within the last 12 months prior to screening. Eligible participants will be randomly assigned in a double-blind manner to either receive plozasiran 25 mg by subcutaneous (SC) injection every three months (Q3M) or matching placebo. Enrolled participants will be counseled to remain on the specified low-fat diet and background medications throughout the study. Following completion of the double-blind treatment period, or if the participant has a positively adjudicated AP event (whichever occurs first), participants will transition to the 12-month Open-Label Extension (OLE) treatment period receiving plozasiran 25 mg by SC injection Q3M.
Phase 3
Recruiting
Clinical Research Site 4 (+9 Sites)Arrowhead Pharmaceuticals
Have you considered Antivert clinical trials? We made a collection of clinical trials featuring Antivert, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security